Frequency and predictors of chemotherapy-associated venous thromboembolism: the prospective PREVENT study.
CONCLUSIONS: VTE occurrence in this real-world patient cohort was high, reaching almost 20% in certain groups, like those with disseminated pancreatic, lung or ovarian cancer receiving first-line chemotherapy. Furthermore, VTE occurs mostly as a symptomatic event, being likely a result of the prothrombotic state of malignancy. PMID: 32057213 [PubMed - as supplied by publisher]
Publication date: Available online 4 April 2020Source: Radiation Physics and ChemistryAuthor(s): B. Juste, R. Miró, S. Morató, G. Verdú, S. Peris
Publication date: Available online 5 April 2020Source: Journal of Molecular StructureAuthor(s): T. Valarmathi, R. Premkumar, A. Milton Franklin Benial
Publication date: Available online 4 April 2020Source: Redox BiologyAuthor(s): Raúl González, María A. Rodríguez-Hernández, María Negrete, Kalina Ranguelova, Aurelie Rossin, Carmen Choya-Foces, Patricia de la Cruz-Ojeda, Antonio Miranda-Vizuete, Antonio Martínez-Ruiz, Sergio Rius-Pérez, Juan Sastre, José A. Bárcena, Anne-Odile Hueber, C. Alicia Padilla, Jordi Muntané
Authors: Chen T, Gilfix B, Rivera JA, Sadeghi N, Richardson K, Hier MP, Forest VI, Fishman D, Caglar D, Pusztaszeri M, Mitmaker EJ, Payne RJ Abstract Though the current gold standard for diagnosing thyroid nodule malignancy is ultrasound-guided fine-needle aspiration (USFNA) cytology, about 20-25% of cytological evaluations are considered indeterminate for malignancy. This limitation has led to the emergence of next-generation sequencing panels, e.g. ThyroSeq v3 (TSv3), which recognize highly-diagnostic genetic mutations of common thyroid carcinomas in FNA samples and classifies them as test-negative or test-positi...
CONCLUSIONS: This study suggests that MTC is a more immunologically active tumor that has been previously reported. Patients with advanced MTC should be screened for targetable antigens and immune checkpoints to determine their eligibility for current clinical trials. Additional studies are necessary to fully characterize the antigenic potential of MTC and may encourage the development of adoptive T cells therapies for this rare tumor. PMID: 32242507 [PubMed - as supplied by publisher]
Publication date: Available online 4 April 2020Source: European Journal of Radiology OpenAuthor(s): Pascal Lomoro, Francesco Verde, Filippo Zerboni, Igino Simonetti, Claudia Borghi, Camilla Fachinetti, Anna Natalizi, Alberto Martegani
Publication date: Available online 4 April 2020Source: Journal of Environmental PsychologyAuthor(s): Kati Peditto, Mardelle Shepley, Naomi Sachs, Jane Mendle, Anthony Burrow
Publication date: Available online 4 April 2020Source: Journal of Minimally Invasive GynecologyAuthor(s): Brunella Zizolfi, Virginia Foreste, Maria Chiara De Angelis, Giovanni Nazzaro, Francesco Paolo Improda, Jose Carugno, Attilio Di Spiezio Sardo
Dr. Matija Snuderl, neuropathologist and molecular pathologist at New York University Langone Health, was featured ina recent article appearing inNature (March 26, 2020, Vol 579, p S14-S16). The article, which addresses the use of artificial intelligence (AI) in cancer diagnostics, opens with Dr. Snuderl experiencing a moment that many of us neuropathologists have had wherein we hesitate before signing out a case because of a feeling that something might be just a bit different about a particular specimen. That feeling prompts us to do something else (run more ancillary testing, get a consult, sleep on it and ta...
This article is protected by copyright. All rights reserved. PMID: 25988873 [PubMed - as supplied by publisher]